Events during January - June 2013:
Laquinimod
· positive results from Phase IIa study of laquinimod in active lupus nephritis
· Teva plans continued clinical development of laquinimod for the treatment of lupus nephritis
· data presented at AAN showed a slower disability progression for multiple sclerosis patients who commenced early treatment with laquinimod compared with delayed treatment
Tasquinimod
· analysis plan for Phase III trial updated; primary PFS analysis expected at the same time as first interim overall survival analysis in 2014
· Phase II follow-up study shows an impact of tasquinimod on bone metastases as measured by
Bone Scan Index (BSI); results presented at ASCO
ANYARA
· improved overall survival in a subgroup of renal cell cancer patients in the Phase II/III study; results presented at ASCO
57-57 (paquinimod)
· clinical trial in systemic sclerosis concluded, evaluation under way
ISI
· patent applications filed
| Jan - Jun | Jan - Dec | ||
| (MSEK) | 2013 | 2012 | 2012 |
| 5.0 | 96.6 | 227.9 |
| -156.5 | -120.6 | -163.2 |
| -159.2 | -123.5 | -175.0 |
| -2.18 | -1.79 | -2.54 |
| 389.1 | 383.7 | 216.7 |
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE- 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
This report is also available at www.activebiotech.com
